100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
123967-58-8Clarithromycin EP Impurity P
● In Stock
| Catalogue No.: | VL740016 |
|---|---|
| CAS No.: | 123967-58-8 |
| Mol. Formula: | C39H71NO13 |
| Mol. Weight: | 761.98 g/mol |
Additional information on CAS 123967-58-8
Parent drug
ClarithromycinIUPAC Name
4′,6-Di-O-methylerythromycin ASynonyms
N/APharmacopeial Synonyms
N/ASmiles
O=C([C@@](C)([H])C[C@@](C)(OC)[C@]([H])(O[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1)[C@@]([C@]([H])(O[C@H]2C[C@@](C)(OC)[C@@H](OC)[C@H](C)O2)[C@@]3([H])C)([H])C)[C@@](C)([H])[C@]([H])([C@](O)([C@]([H])(OC3=O)CC)C)OInChI
InChI=1S/C39H71NO13/c1-16-27-39(10,45)32(43)22(4)29(41)20(2)18-37(8,47-14)33(53-36-30(42)26(40(11)12)17-21(3)49-36)23(5)31(24(6)35(44)51-27)52-28-19-38(9,48-15)34(46-13)25(7)50-28/h20-28,30-34,36,42-43,45H,16-19H2,1-15H3/t20-,21-,22+,23+,24-,25+,26+,27-,28+,30-,31+,32-,33-,34+,36+,37?,38?,39-/m1/s1Description
Clarithromycin EP Impurity P (CAS 123967-58-8) is a macrolide-related process impurity associated with the 14-membered erythromycin-derived scaffold and the dense O-methylation pattern characteristic of clarithromycin analogues. With molecular formula C39H71NO13 and molecular weight 761.98 g/mol, it represents a structurally defined minor component that may arise during semisynthetic transformation or oxidative, hydrolytic, or epimerization pathways affecting the lactone and cladinose domains. Its assignment typically requires orthogonal characterization by LC-MS/MS, HRMS, and NMR, with chromatographic separation by HPLC or UPLC. In regulatory impurity profiling, it is evaluated as a non-nitrosamine structural impurity within pharmacopeial specifications.References
MORIMOTO, SHIGEO, et al. “Chemical Modification of Erythromycins. II. Synthesis and Antibacterial Activity of O-Alkyl Derivatives of Erythromycin A.†The Journal of Antibiotics, vol. 43, no. 3, 1990, pp. 286–94, https://doi.org/10.7164/antibiotics.43.286. ‌Griffith, R. S., and H. R. Black. “Erythromycin.†Medical Clinics of North America, vol. 54, no. 5, Sept. 1970, pp. 1199–215, https://doi.org/10.1016/s0025-7125(16)32587-1. ‌Request a Quote
"*" indicates required fields
Other products related to Clarithromycin impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
Clarithromycin
CAS No. 81103-11-9
Cat No. PVE0023
